Wedbush Reiterates an 'Outperform' on AVI BioPharma (AVII); Sell-Off Misses Point; Higher Dose Hit Endpoint
Tweet
Share
E-mailGet Alerts AVII Hot Sheet
Price: $0.66 --0%
Rating Summary:
4 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 6 | New: 6
Rating Summary:
4 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 6 | New: 6
Join SI Premium – FREE
Wedbush reiterates an 'Outperform' on AVI BioPharma (NASDAQ: AVII) price target of $2.50.
Analyst, Gregory R. Wade, said, "AVII reported top-line results from its Phase IIb trial of eteplirsen in boys with Duchenne muscular dystrophy (DMD). Patients receiving the 30 mg/kg dose over 24 weeks met the primary endpoint of increasing levels of dystrophinpositive fibers by a mean 22.5%, the largest effect seen to date with eteplirsen. The higher dose of 50 mg/kg did not show a statistically significant protein response, but recall that it was dosed only over 12 weeks, supporting long-term eteplirsen dosing."
Wade also noted some confusion in clinical stats and shares having significantly declined, but Wade is confident in significantly increased dystrophin levels at 24 wks with the 30 mg/kg dose as likely to lead to improved clinical outcomes.
For an analyst ratings summary and ratings history on AVI BioPharma click here. For more ratings news on AVI BioPharma click here.
Shares of AVI BioPharma closed at $1.54 yesterday.
Analyst, Gregory R. Wade, said, "AVII reported top-line results from its Phase IIb trial of eteplirsen in boys with Duchenne muscular dystrophy (DMD). Patients receiving the 30 mg/kg dose over 24 weeks met the primary endpoint of increasing levels of dystrophinpositive fibers by a mean 22.5%, the largest effect seen to date with eteplirsen. The higher dose of 50 mg/kg did not show a statistically significant protein response, but recall that it was dosed only over 12 weeks, supporting long-term eteplirsen dosing."
Wade also noted some confusion in clinical stats and shares having significantly declined, but Wade is confident in significantly increased dystrophin levels at 24 wks with the 30 mg/kg dose as likely to lead to improved clinical outcomes.
For an analyst ratings summary and ratings history on AVI BioPharma click here. For more ratings news on AVI BioPharma click here.
Shares of AVI BioPharma closed at $1.54 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Siemens Ltd. (SIEM:IN) PT Raised to INR3,000 at BofA Securities
- UBS Downgrades Nihon Kohden Corp (6849:JP) to Neutral
- Deutsche Bank Upgrades Entegris Inc (ENTG) to Buy
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
